MBMaría Bastianello

María Bastianello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


María Bastianello has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ⁶⁸Ga-DOTATATE PET/CT Findings in Suspected Tumor-Induced Osteomalacia

    by María Bastianello, Roxana Chirico, Matías Cimín, María Belén Zanchetta

    Objective. To describe ⁶⁸Ga-DOTATATE PET/CT findings and their relationship to available histopathology in patients referred for suspected tumor-induced osteomalacia. Methods. This prospective descriptive study included 18 patients evaluated at a referral center in Argentina. Results. The median age was 47.5 years and 13 of 18 patients were women. The reported median SUVmax was 17.2 (interquartile range 6.27–30.6). Lesions were most frequently reported in the appendicular skeleton. Eight patients had histologically confirmed phosphaturic mesenchymal tumors (PMTs). Two of these eight patients had lesions with ill-defined margins and involvement of soft tissue and facial bones. Median SUVmax was numerically higher in the PMT group. The difference was not statistically significant as reported. Conclusion. In this referral cohort, ⁶⁸Ga-DOTATATE PET/CT helped localize and characterize lesions in patients with suspected tumor-induced osteomalacia. Confirmed PMTs showed variable morphology. The findings support descriptive interpretation in conjunction with histopathology and clinical assessment.

  • Open Access

    Aortitis as Cause of Chest Pain: Role of FDG-PET in a Multimodal Diagnostic Approach

    by Mario Mera, Alex Kostianovsky, Diego Herrera Vegas, Javier Vallejos, María Bastianello

    Diagnostic imaging plays a critical role in identifying aortitis. (1) Computed tomography (CT) angiography of the aorta and thoracic magnetic resonance imaging (MRI) are essential resources to discriminate the different causes of chest pain. Nonetheless, once the aorta is identified as responsible for the symptoms, there are several conditions that can cause confusion in the diagnosis of aortitis, such as acute aortic syndrome (intramural hematoma, aortic dissection, and penetrating atherosclerotic ulcer) and different types of stent-graft leaks. Inflammation of the aortic wall may be caused by inflammatory, infectious, paraneoplastic or idiopathic diseases. Use of radioisotope techniques such as 18-fluorodeoxyglucose positron emission tomography (18 F-FDG PET) is an accurate tool for the diagnosis of this infectious or noninfectious inflammation. (2) We report the case of a patient with chest pain, where PET/CT scan revealed an aortic inflammatory process that redefined the diagnosis and treatment. This 74-year-old male patient was a heavy smoker and had hypertension and dyslipidemia. A control chest CT scan after radiation therapy for laryngeal cancer revealed an atherosclerotic, penetrating aortic ulcer, with maximum diameter of 22 mm in the lower wall of the juxtaductal region, which was treated with a thoracic stent-graft. The patient progressed with recurrent chest pain requiring new hospitalization. The condition was interpreted as of coronary etiology, and a coronary angiography (CA) with angioplasty and stent placement in the mid-circumflex artery was therefore performed. The patient was always afebrile, but was admitted in our center due to persistent chest pain. Lab tests on admission showed white blood cell count of 10 600/mm 3; erythrocyte sedimentation rate (ESR), 92 mm/h; C-reactive protein (CRP), 12.7 mg/ dL; high-sensitivity troponin T, 117 mg/dL; and negative blood cultures. A new CA showed no lesions and a patent stent. Thoracic aortography ruled out aortic dissection and stent-graft endoleaks. An 18 F-FDG PET/CT scan (Figure 1) exposed a thickened aortic arch wall, with intravenous contrast enhancement and radiotracer uptake with a maximum standardized uptake value (SUVmax) of 14.4, predominantly in the medial sector and, to a lesser extent, in the inferior sector. The ulcer was properly excluded with no evidence of endoleaks or expansion. The aortic stent showed no signs of pathological uptake. Due to suspected diagnosis of inflammatory aortitis, systemic inflammatory markers were requested, including VDRL, FTA-Abs, FAN in Hep-2, ANCA c and p, HLA-B*51 (for Behçet’s disease), and IgG4, with negative results. The condition was thus interpreted as isolated aortitis after aortic stent graft placement in the context of preexisting inflammatory aortic disease. Although giant cell arteritis —an entity accounting for 70% of aortitis in patients >50 years of age, and involving the aortic wall in 15-22% of cases in a diffuse or segmental form, with high probability of causing aortic aneurysms— cannot be definitively ruled out as a differential diagnosis, (3) this diagnosis is unlikely in our case as the patient did not meet the classification criteria or the typical clinical manifestations. The patient was started on meprednisone and made good progress, with resolution of symptoms and normalization of inflammatory parameters (ESR and CRP). A follow-up 18 F-FDG PET/CT scan at 2 months (Figure 2) showed persistent metabolic activity in the medial and inferior wall of the aortic arch, extending to the lateral sector, and the same uptake values as in the previous study. Aortitis is a nonspecific term that refers to inflammatory changes in the aortic wall, often caused by a systemic inflammatory, infectious or non-infectious disease, with different clinical variables and presentation. Therefore, the diagnosis often requires a multimodal imaging approach. (4) In our patient, after an initial CT angiography and two invasive procedures, a PET/CT scan made it possible to redefine the diagnosisinitially oriented to a coronary disease, as aortitis. FDG PET for the diagnosis of inflammatory aortic disease has 98% specificity, a positive predictive value of 93%, and a negative predictive value of 80%. (5) These data are also relevant for the follow-up and treatment of these patients, based on the inflammatory activity provided by the images and the evolving clinical and serological data. (6) Conflicts of interest None declared.(See authors’ conflicts of interest forms on the website/Supplementary material).


  • Open Access

    Imágenes moleculares de un paraganglioma cardíaco

    by Roxana Chirico, Matías Cimin, Andrea De Salazar, María Bastianello

  • Open Access

    Imágenes moleculares de un paraganglioma cardíaco

    by Roxana Chirico, Matías Cimin, Andrea De Salazar, María Bastianello

  • Open Access

    Exploring the applicability of a lesion segmentation method on [18F]fluorothymidine PET/CT images in diffuse large B-cell lymphoma

    by Germán Pitarch, Yamila Rotstein Habarnau, Roxana Chirico, Brenda Konowalik, Amalia Pérez, Alejandro Valda, María Bastianello

    Background and purpose: The determination of the total metabolic tumour volume based on [18F]fluorothymidine ([18F]FLT) PET/CT images in diffuse large B-cell lymphoma has a potential clinical value for detecting early relapse in this type of heterogeneous lymphoproliferative tumours. Tumour segmentation is a key step in this process. For this purpose, our objective was to determine a segmentation threshold of [18F]FLT PET/CT images, based on a reference tissue uptake, on a cohort of patients with diffuse large B-cell lymphoma (DLBCL) that have been scanned at different stages of the treatment. Methods: We enrolled 23 adult patients with DLBCL confirmed in II-IV stages without nervous system compromise. All patients were scanned using [18F]FLT PET/CT at the time of diagnosis (baseline PET), interim PET (iPET), and at the end of treatment (fPET). The administered activity was 1.8–2.6 MBq/kg body weight, performed 60–70 min after injection and without use of contrast-enhanced CT. First, we assessed the [18F]FLT uptake stability in liver and bone marrow along the patient follow-up. For the lesion segmentation, three threshold values were assessed. Results: Both, liver, and bone marrow can be indistinctly taken as reference tissue. The SUV threshold for a voxel to be considered as belonging to a lesion is expressed in terms of a percentage relative to the patient’s uptake in the reference tissue. Found thresholds were: for liver, 62%, 33%, 27%; and for bone marrow, 35%, 21% and 22%, for baseline, iPET and fPET stages, respectively. The relative threshold throughout the treatment has a decreasing tendency along the stages. Conclusion: Based on the results obtained with [18F]FLT PET/CT during staging and follow-up in patients with DLBCL, reference values were obtained for each stage referring to liver and bone marrow uptake that could be used in clinical practice oncology.

  • PET/TC 18F-PSMA para localización anatómica de las recurrencias en el cáncer de próstata

    by Juan Bautista Blaquier, María José Bastianello, Martín Greco, Gonzalo Recondo (H), Gonzalo Recondo, Fernando Galanternik

    En la recaída bioquímica posterior al tratamiento definitivo en cáncer de próstata, la localización anatómica y extensión de la enfermedad son fundamentales para definir el tratamiento. Métodos como tomografía computada (TC), centellograma óseo (CO), resonancia magnética (RNM) y PET-Colina son utilizados a pesar de su baja sensibilidad. El PET-PSMA demostró mayor sensibilidad y especificidad que estos estudios, inclusive con bajos niveles de PSA. El objetivo de nuestro trabajo fue evaluar la tasa de detección de enfermedad utilizando PET-PSMA en pacientes con adenocarcinoma de próstata con ascenso de PSA luego de tratamiento definitivo local y su asociación con los valores de PSA. Se incluyeron 45 pacientes con una mediana de edad de 62 años (RIC 60-67). El 55% realizó cirugía como tratamiento primario y 40% tenían un score de Gleason ≥ 8. La mediana de PSA fue de 3.5 ng/ml (RIC 1.1-7.2). Se localizó el sitio de recurrencia en 41 pacientes (91%), con un rédito en base al valor de PSA de: 40% <0.5 ng/ml, 100% 0.5 a <1 ng/ml, 100% 1 a <2 ng/ml, 92% 2 a <5 ng/ml y 100% ≥5 ng/ml. El 58% de los pacientes tenían enfermedad metastásica. En nuestro estudio el uso de PET-PSMA tuvo una alta tasa de detección de sitio de recaída.

  • Prospective study on the clinical relevance of 18F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma

    by Inés Califano, Fabián Pitoia, Roxana Chirico, Alejandra De Salazar, María José Bastianello

    Purpose 18F-DOPA Positron Emission Tomography/Computed Tomography (18F-DOPA PET/CT) is a sensitive functional imaging method (65–75%) for detecting disease localization in medullary thyroid cancer (MTC). We aimed: (i) to assess the clinical usefulness of 18F-DOPA PET/CT in patients with MTC and elevated calcitonin (Ctn) and CEA levels and, (ii) to evaluate changes in disease management secondary to the findings encountered with this methodology. Methods Thirty-six patients with MTC and Ctn levels ≥150 pg/ml were prospectively included. Neck ultrasound, chest contrast-enhanced CT, liver magnetic resonance imaging/abdominal three-phase contrast-enhanced CT and bone scintigraphy were carried out up to 6 months before the 18F DOPA PET/CT. Results Seventy eight percent of patients were female and 27% had hereditary MTC. Median Ctn level was 1450 pg/ml [150–56620], median CEA level 413 ng/ml [2.9–7436]. Median Ctn DT was 37.5 months [5.7–240]; median CEA DT was 31.8 [4.9–180]. 18F-DOPA PET/CT was positive in 33 patients (91.6%); in 18 (56%) uptake was observed in lymph nodes in the neck or mediastinum, in seven cases (22%) distant metastases were diagnosed, and in eight additional patients (24%) both locoregional and distant sites of disease were found. Ctn and CEA levels were higher in patients with ≥3 foci of distant metastases. In 14 patients (38.8%), findings on 18F-DOPA PET/CT led to changes in management; surgery for locoregional lymph nodes was the most frequent procedure in 8 patients (22%). Conclusion 18F-DOPA PET/CT was useful for the detection of recurrent disease in MTC, providing incremental value over conventional imaging procedures that led to modification in treatment strategies in nearly 40% of patients.


  • Aortitis as Cause of Chest Pain: Role of FDG-PET in a Multimodal Diagnostic Approach

    by Mario Mera, Alex Kostianovsky, Diego Herrera Vegas, Javier Vallejos, María Bastianello